Zyrovazet 10/5 mg 30 tablets

Zyrovazet 10 mg/5 mg

30 film coated tablets

Composition:

Rosuvastatin 5 mg

Ezetimibe 10 mg

Inactive ingredients:

Microcrystalline cellulose, lactose monohydrate, dicalcium phosphate anhydrous, PVP K30, crospovidone, poloxamer 407, sodium lauryl sulfate, croscarmellose sodium, silicone dioxide, magnesium stearate

 Properties:

Zyrovazet is a medicine that combines rosuvastatin and ezetimibe to lower cholesterol.

Zyrovazet  tablets are used in adults to lower levels of total cholesterol, “bad” cholesterol, and triglycerides in the blood. In addition, it increases levels of good cholesterol.

Zyrovazet tablets reduce cholesterol in two ways, by reducing the amount of cholesterol absorbed in the digestive tract, as well as the cholesterol made by the body.

Cholesterol is one of many fatty substances found in the blood. Total cholesterol consists mainly of “bad” cholesterol and “good” cholesterol. Low-density lipoprotein (LDL) cholesterol is often called “bad” cholesterol because it can accumulate In the walls of the arteries forming plaques or deposits, the buildup of these plaques can eventually lead to narrowing of the arteries. This narrowing can slow or block blood flow to vital organs such as the heart and brain. Blocking blood flow can lead to heart attacks or strokes. 

High-density lipoprotein (HDL) cholesterol is often called the “good” cholesterol because it helps prevent harmful cholesterol from building up in the arteries and protects against heart disease.

Triglycerides are another form of fat in the blood that may increase the risk of heart disease.

This medicine is used for patients whose cholesterol levels cannot be controlled by diet alone. You must adhere to a cholesterol-lowering diet while using Zyrovazet.

Rosuvastatin lowers cholesterol as it is the specific inhibitor (3 hydroxy-3-methyl-glutril coenzyme A-reductase) that converts (HMG-CoA) to mevalonate which is an essential step that limits the biosynthesis of cholesterol. The enzyme catalyzing the conversion of rosuvastatin lowers total cholesterol, LDL cholesterol ApoB in familial and non-familial hypercholesterolemia and variant forms of dyslipidemias, rosuvastatin also lowers VLDL-cholesterol and triglycerides and leads to increased levels of HDL-cholesterol.

Ezetimibe: reduces cholesterol in the blood by blocking the absorption of cholesterol from the small intestine. It reduces total LDL cholesterol, triglycerides and increases levels of HDL cholesterol.

The combination of rosuvastatin and ezetimibe is effective in improving levels of total “bad” LDL cholesterol, triglycerides, and “good” HDL cholesterol along with the individual effect of each compound.

Indications:

-As a treatment with a diet to reduce elevated total cholesterol and LDL cholesterol.

-As an adjunct with diet to treat patients with elevated triglyceride levels.

-With heart patients to reduce the rise of LDL cholesterol to less than 100 mg / dl.

-Homozygous familial cases of high cholesterol.

Dosage and administration:

This medicine should be taken according to the doctor’s instructions.

The initial and continuous dose varies from one patient to another according to the goal of treatment and the response to it.

The recommended dose of Zyrovazet is one tablet daily, with or without food. The doctor will determine the appropriate concentration for your condition.

No dose adjustment in patients with renal failure.

It is not recommended to take Zyrovazet with patients who suffer from impaired liver function.

Side effects:

Upper respiratory infection

Headache and stress

Muscle and back pain

Sinusitis and pharynx

Diarrhea and abdominal pain

Contraindications:

-Hypersensitivity to rosuvastatin or ezetimibe;

-Severe liver disease;

-Pregnant and lactating women.

Warnings and precautions:

• Caution should be taken when using Zyrovazet with erythromycin, as this may lead to an increase in the plasma levels of rosuvastatin.
• Zyrovazet should be used with caution in patients who drink excessive amounts of alcohol or have liver disease.
• Zyrovazet should be temporarily discontinued if the patient develops symptoms of polymyositis or if he develops renal failure due to rhabdomyolysis.
• Caution should be exercised when Zyrovazet is taken with preparations that may reduce the levels of endogenous activity or steroid hormones such as ketoconazole, spironolactone, cimetidine.

If you suffer from hereditary problems of incompatibility with some sugars, do not take this medicine as it contains lactose.

• Zyrovazet is not used during pregnancy and lactation. It is used with women of childbearing age only with cases with which pregnancy is unlikely and fully aware of the potential risks.
• Keep out of reach of children.

Storage:

Store at a temperature not exceeding 30°C

Package:

Carton box holds 3 strips each of 10 film coated tablets and paper instructions.